UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 7, 2010

 

 

Icagen, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-34217   56-1785001

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

4222 Emperor Boulevard, Suite 350

Durham, North Carolina

  27703
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (919) 941-5206

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events.

On October 11, 2010, Icagen, Inc. (the “Company”) issued a press release announcing that it has regained compliance with the Nasdaq Global Market’s $1.00 minimum bid price requirement. On October 7, 2010, the Company received notification from the Nasdaq Listing Qualifications Department that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) after maintaining a closing bid price equal to or in excess of $1.00 for a minimum of ten consecutive trading days and that the Company’s non-compliance with the requirement announced on November 13, 2009, has been rectified.

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ICAGEN, INC.

Date: October 12, 2010

  By:  

/s/ Richard D. Katz

    Richard D. Katz
   

Executive Vice President, Finance and

Corporate Development and Chief Financial

Officer

EXHIBIT INDEX

 

Exhibit No.

 

Description

99.1

  Press Release entitled “Icagen Regains Compliance with Nasdaq Listing Requirements” issued by the Company on October 11, 2010
Icagen, Inc. (MM) (NASDAQ:ICGND)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Icagen, Inc. (MM) Charts.
Icagen, Inc. (MM) (NASDAQ:ICGND)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Icagen, Inc. (MM) Charts.